Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 35.20

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (75)	12/17/2002 2:30:12 PM
From: tuck	Read Replies (1) of 566

Well, these guys are about due: >>During the company's presentation at the CIBC World Markets Healthcare Conference, Rigel said that it intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the company's first product, R112 for allergic rhinitis, before the end of the year.<< This form the 3rd Q PR, you may recall. And here it is plumbing bottom. I wonder if they have talked about partnering any of their unpartnered programs. failing that, I agree hibernation is the best thing. Am tempted to take a flyer at these levels. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next